European Investor
19 Feb 2026, 19:00
DHL Group has expanded its dedicated Airfreight Cold Chain Network to strengthen global Life Sciences & Healthcare logistics, supporting the secure transport of temperature-sensitive medicines, vaccines, biologics, and cell and gene therapies.
The expansion, part of DHL’s EUR 2 billion investment in DHL Health Logistics, connects more than 30 GDP-compliant aviation hubs worldwide and reduces reliance on third-party carriers, improving temperature control, product integrity, and supply chain resilience.
The network initially links key hubs including Brussels (BRU) and Cincinnati (CVG), creating a direct, temperature-controlled corridor between major U.S. and European pharma markets. The Brussels hub is supported by 45,000 square meters of dedicated pharma facilities at BRUcargo.
A newly introduced Boeing 777 freighter, branded “DHL Health Logistics,” will operate on the BRU–CVG route, providing dedicated capacity and enhanced reliability for critical healthcare shipments.
The expansion, part of DHL’s EUR 2 billion investment in DHL Health Logistics, connects more than 30 GDP-compliant aviation hubs worldwide and reduces reliance on third-party carriers, improving temperature control, product integrity, and supply chain resilience.
The network initially links key hubs including Brussels (BRU) and Cincinnati (CVG), creating a direct, temperature-controlled corridor between major U.S. and European pharma markets. The Brussels hub is supported by 45,000 square meters of dedicated pharma facilities at BRUcargo.
A newly introduced Boeing 777 freighter, branded “DHL Health Logistics,” will operate on the BRU–CVG route, providing dedicated capacity and enhanced reliability for critical healthcare shipments.